<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760069</url>
  </required_header>
  <id_info>
    <org_study_id>C.2016.091</org_study_id>
    <nct_id>NCT02760069</nct_id>
  </id_info>
  <brief_title>Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department</brief_title>
  <official_title>Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brooke Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the efficacy of isopropyl alcohol and conventional anti-emetics with
      three study arms: (1) inhaled isopropyl alcohol plus oral ondansetron; (2) inhaled isopropyl
      alcohol plus oral placebo; (3) inhaled placebo plus oral ondansetron.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective randomized controlled trial to test the hypothesis that
      nasally-inhaled isopropyl alcohol (ISO) plus oral placebo has greater anti-emetic efficacy
      compared to oral ondansetron oral solution. By design, the study will be double-blinded
      insofar as neither investigators nor subjects will be notified of the identity of the
      substances they are inhaling or swallowing. The study will include a post-study survey to
      ascertain the extent to which blinding was achieved. Potential subjects are those presenting
      to the Emergency Department (ED) with nausea and/or vomiting. Investigators will recruit a
      convenience sample by approaching subjects at the time of initial triage and solicit nausea
      on a verbal numerical rating scale (VNRS) scored from 0-10 with those patients reporting
      scores of 3 or greater eligible for study. Informed consent will be obtained from each
      subject.

      Subjects will be allocated to one of three arms: (1) inhaled isopropyl alcohol plus oral
      ondansetron; (2) inhaled isopropyl alcohol plus oral placebo; (3) inhaled placebo plus oral
      ondansetron. No subject will receive both inhaled and oral placebo; all subjects will be
      allocated to at least one therapeutic intervention for nausea. Both investigators and study
      subjects will be blinded to subject allocation.

      Regarding the interventions, upon recruitment, patients will be administered an oral solution
      (placebo or ondansetron) by their treating nurse. A study team member will then instruct the
      subject to inhale one of the blinded prep pads, to hold the pad approximately 1 centimeter
      from their nares, and to take deep nasal inhalations as needed for nausea relief. The
      investigator will remain at arm's length from the patient at all times to avoid detecting
      prep pad scent. Additionally, investigators will also instruct subjects to avoid any behavior
      or actions during the study that would indicate which preparation pad is being used.

      The investigators will record their findings on data collection forms. The primary outcome
      will be nausea as measured on a 10 cm visual analogue scale (VAS) at 30 minutes. Nausea
      measurements will also be collected at 10, 20, 40, 50, and 60 minutes, and then every hour up
      to 5 hours, then at disposition at which time the patient will provide one final nausea VAS
      score. The study team member will not be present in the patient's room during the intervals
      between these evaluations. At the time of each nausea measurement, patients will be offered
      another preparation pad (up to ten pads). Investigators will notify the patient's treating
      provider to prompt consideration for treatment with a rescue anti-emetic (such as
      metoclopramide or promethazine) if the patient vomits or if the patient requests an
      anti-emetic at any time. At the time of each nausea measurement, a pain score will also be
      measured on a 10 cm VAS. At the time of final disposition, the patient will provide a
      satisfaction score on a 10-cm VAS and be asked to indicate his/her belief as to whether the
      pad was a treatment or placebo and whether the oral solution was a treatment or placebo.
      Similarly, at study conclusion the patient's provider will be asked to indicate his/her
      belief as to whether the pad was a treatment or placebo and whether the oral solution was a
      treatment or placebo. Other data collected will include times and doses for all medications
      (including preparation pads) and fluids administered, episodes of vomiting (defined as
      forceful expulsion of gastric contents separated by at least 2 minutes), disposition
      (admission versus discharge), final clinical impression at the time of disposition, and time
      to disposition. Subjects will be followed and data collected for the entirety of their ED
      stay.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nausea 100 mm Visual Analogue Scale (VAS)</measure>
    <time_frame>30 minutes post intervention</time_frame>
    <description>Full Scale Name: Nausea 100-mm visual analogue scale. Scale Construct: Measures nausea as reported by the patient Scale Range: Minimum is 0 (no nausea) to 100 (worst nausea imaginable). These values quantify, on an interval scale anchored at 0, the patient's subjective sensation of nausea. Higher values represent worse outcomes (e.g., more nausea). Patient makes a single vertical mark on a 100 mm horizontal line with 0 at the left and 100 on the right to depict their nausea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Required Rescue Anti-emetics</measure>
    <time_frame>Study duration (up to 5 hours post intervention)</time_frame>
    <description>Whether patient required rescue anti-emetics (binary variable). Measured using nurse drug administration record.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>Inhaled ISO + oral ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled ISO + oral placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled placebo + oral ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled isopropyl alcohol</intervention_name>
    <description>Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.</description>
    <arm_group_label>Inhaled ISO + oral ondansetron</arm_group_label>
    <arm_group_label>Inhaled ISO + oral placebo</arm_group_label>
    <other_name>ISO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral ondansetron</intervention_name>
    <description>Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.</description>
    <arm_group_label>Inhaled ISO + oral ondansetron</arm_group_label>
    <arm_group_label>Inhaled placebo + oral ondansetron</arm_group_label>
    <other_name>Ondansetron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled normal saline</intervention_name>
    <description>Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.</description>
    <arm_group_label>Inhaled placebo + oral ondansetron</arm_group_label>
    <other_name>Inhaled placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <description>Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00</description>
    <arm_group_label>Inhaled ISO + oral placebo</arm_group_label>
    <other_name>Oral sugar water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 18 and older

          -  complaint of nausea and/or vomiting reported at 3 or above on verbal numerical rating
             scale at the time of triage

        Exclusion Criteria:

          -  allergy to isopropyl alcohol or ondansetron

          -  inability to breathe through nose (e.g., recent upper respiratory infection)

          -  intake of cefoperazone, disulfiram, or metronidazole within the last 24 hours

          -  mental status precluding informed consent including intoxication

          -  known QT-prolongation

          -  clinical suspicion for serotonin syndrome

          -  intravenous catheter in place prior to study start

          -  medications administered since patient arrival (e.g., in triage)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D April, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beadle KL, Helbling AR, Love SL, April MD, Hunter CJ. Isopropyl Alcohol Nasal Inhalation for Nausea in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2016 Jul;68(1):1-9.e1. doi: 10.1016/j.annemergmed.2015.09.031. Epub 2015 Dec 8.</citation>
    <PMID>26679977</PMID>
  </reference>
  <reference>
    <citation>Hines S, Steels E, Chang A, Gibbons K. Aromatherapy for treatment of postoperative nausea and vomiting. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD007598. doi: 10.1002/14651858.CD007598.pub2. Review. Update in: Cochrane Database Syst Rev. 2018 Mar 10;3:CD007598.</citation>
    <PMID>22513952</PMID>
  </reference>
  <reference>
    <citation>Egerton-Warburton D, Meek R, Mee MJ, Braitberg G. Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. Ann Emerg Med. 2014 Nov;64(5):526-532.e1. doi: 10.1016/j.annemergmed.2014.03.017. Epub 2014 May 10.</citation>
    <PMID>24818542</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>May 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <results_first_submitted>July 8, 2019</results_first_submitted>
  <results_first_submitted_qc>July 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2020</results_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brooke Army Medical Center</investigator_affiliation>
    <investigator_full_name>Michael D. April</investigator_full_name>
    <investigator_title>Assistant Program Director for Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Nausea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02760069/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inhaled ISO + Oral Ondansetron</title>
          <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.</description>
        </group>
        <group group_id="P2">
          <title>Inhaled ISO + Oral Placebo</title>
          <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral placebo: Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00</description>
        </group>
        <group group_id="P3">
          <title>Inhaled Placebo + Oral Ondansetron</title>
          <description>Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
Inhaled normal saline: Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled ISO + Oral Ondansetron</title>
          <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.</description>
        </group>
        <group group_id="B2">
          <title>Inhaled ISO + Oral Placebo</title>
          <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral placebo: Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00</description>
        </group>
        <group group_id="B3">
          <title>Inhaled Placebo + Oral Ondansetron</title>
          <description>Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
Inhaled normal saline: Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nausea 100-mm visual analogue scale</title>
          <description>Full Scale Name: Nausea 100-mm visual analogue scale. Scale Construct: Measures nausea as reported by the patient Scale Range: Minimum is 0 (no nausea) to 100 (worst nausea imaginable). These values quantify, on an interval scale anchored at 0, the patient's subjective sensation of nausea. Higher values represent worse outcomes (e.g., more nausea). Patient makes a single vertical mark on a 100 mm horizontal line with 0 at the left and 100 on the right to depict their nausea.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="22"/>
                    <measurement group_id="B2" value="51" spread="21"/>
                    <measurement group_id="B3" value="51" spread="20"/>
                    <measurement group_id="B4" value="52" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nausea 100 mm Visual Analogue Scale (VAS)</title>
        <description>Full Scale Name: Nausea 100-mm visual analogue scale. Scale Construct: Measures nausea as reported by the patient Scale Range: Minimum is 0 (no nausea) to 100 (worst nausea imaginable). These values quantify, on an interval scale anchored at 0, the patient's subjective sensation of nausea. Higher values represent worse outcomes (e.g., more nausea). Patient makes a single vertical mark on a 100 mm horizontal line with 0 at the left and 100 on the right to depict their nausea.</description>
        <time_frame>30 minutes post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled ISO + Oral Ondansetron</title>
            <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled ISO + Oral Placebo</title>
            <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral placebo: Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Placebo + Oral Ondansetron</title>
            <description>Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
Inhaled normal saline: Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea 100 mm Visual Analogue Scale (VAS)</title>
          <description>Full Scale Name: Nausea 100-mm visual analogue scale. Scale Construct: Measures nausea as reported by the patient Scale Range: Minimum is 0 (no nausea) to 100 (worst nausea imaginable). These values quantify, on an interval scale anchored at 0, the patient's subjective sensation of nausea. Higher values represent worse outcomes (e.g., more nausea). Patient makes a single vertical mark on a 100 mm horizontal line with 0 at the left and 100 on the right to depict their nausea.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="25"/>
                    <measurement group_id="O2" value="19" spread="18"/>
                    <measurement group_id="O3" value="42" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Required Rescue Anti-emetics</title>
        <description>Whether patient required rescue anti-emetics (binary variable). Measured using nurse drug administration record.</description>
        <time_frame>Study duration (up to 5 hours post intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled ISO + Oral Ondansetron</title>
            <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled ISO + Oral Placebo</title>
            <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral placebo: Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Placebo + Oral Ondansetron</title>
            <description>Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
Inhaled normal saline: Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Required Rescue Anti-emetics</title>
          <description>Whether patient required rescue anti-emetics (binary variable). Measured using nurse drug administration record.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of study (up to 5 hours)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inhaled ISO + Oral Ondansetron</title>
          <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.</description>
        </group>
        <group group_id="E2">
          <title>Inhaled ISO + Oral Placebo</title>
          <description>Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Inhaled isopropyl alcohol: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Oral placebo: Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00</description>
        </group>
        <group group_id="E3">
          <title>Inhaled Placebo + Oral Ondansetron</title>
          <description>Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
Oral ondansetron: Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
Inhaled normal saline: Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael D. April</name_or_title>
      <organization>Brooke Army Medical Center</organization>
      <phone>210-916-0808</phone>
      <email>Michael.D.April.mil@mail.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

